Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 Pandemic Waltham, MA.

Enrollment in the U.S. Phase

2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 Pandemic

Waltham, MA. - August 12, 2020 - Eloxx

Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company

dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense

mutations limiting production of functional proteins, today announced that enrollment in its Phase 2 clinical trial for ELX-02

in cystic fibrosis has resumed at certain clinical sites in the U.S. after being temporarily paused in response to the COVID-19

pandemic. On June 17, 2020, we announced that enrollment had been resumed in the Phase 2 clinical trial in cystic fibrosis in

Europe and Israel after a temporary pause due to the COVID-19 pandemic.

"We are pleased that enrollment in our

Phase 2 clinical trial program in cystic fibrosis has now resumed in the U.S., Israel and Europe, following temporary pauses due

to the COVID-19 pandemic. Our highest priority is to complete the Phase 2 proof of concept clinical trial program and report top

line data as soon as possible," said Dr. Gregory Williams, Chief Executive Officer of Eloxx. "We are grateful for

the continued support and guidance from leading cystic fibrosis clinical investigators and our Cystic Fibrosis Medical Advisory

Board members throughout the development, conduct and resumption of our Phase 2 clinical trial program."

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical

company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated

to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis

from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production

from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature

stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused

on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop

codons to produce full-length proteins. Eloxx's lead investigational product candidate, ELX-02, is a small molecule drug

candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development

focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx's

preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides

identified based on read-through potential. Eloxx also has preclinical programs focused on kidney diseases including autosomal

dominant polycystic kidney disease, as well as rare ocular genetic disorders. Eloxx is headquartered in Waltham, MA, with operations

in Rehovot, Israel and Morristown, NJ. For more information, please visit www.eloxxpharma.com.

Forward-Looking Statements

contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements

can be identified by the words "expects," "anticipates," "believes," "intends," "estimates,"

"plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's

current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation

to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking

statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control.

Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact

of a number of factors, including: the development of the Company's read-through technology; the approval of the Company's

patent applications; the Company's ability to successfully defend its intellectual property or obtain necessary licenses

at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development

programs and collaborations; the Company's ability to obtain applicable regulatory approvals for its current and future

product candidates; the acceptance by the market of the Company's products should they receive regulatory approval; the

timing and success of the Company's preliminary studies, preclinical research, clinical trials, and related regulatory filings;

the ability of the Company to consummate additional financings as needed; the impact of global health concerns, such as the COVID-19

global pandemic, on our ability to continue our clinical and preclinical programs and otherwise operate our business effectively;

as well as those discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities

and Exchange Commission.